[{"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 45, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1193748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory S. Zante CPA, CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 713000, "exercisedValue": 20395892, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 735000, "exercisedValue": 8888907, "unexercisedValue": 636903}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 59, "title": "Vice President of Finance & Administration", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 375333, "exercisedValue": 0, "unexercisedValue": 490518}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 28.615, "open": 29.18, "dayLow": 29.1, "dayHigh": 30.28, "regularMarketPreviousClose": 28.615, "regularMarketOpen": 29.18, "regularMarketDayLow": 29.1, "regularMarketDayHigh": 30.28, "payoutRatio": 0.0, "beta": 0.831, "forwardPE": -19.443708, "volume": 4424955, "regularMarketVolume": 4424955, "averageVolume": 4844451, "averageVolume10days": 4541410, "averageDailyVolume10Day": 4541410, "bid": 28.86, "ask": 30.09, "bidSize": 30, "askSize": 30, "marketCap": 3297421568, "fiftyTwoWeekLow": 18.92, "fiftyTwoWeekHigh": 81.86, "fiftyDayAverage": 26.6683, "twoHundredDayAverage": 46.3132, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2446550272, "profitMargins": 0.0, "floatShares": 109876920, "sharesOutstanding": 112310000, "sharesShort": 25463291, "sharesShortPriorMonth": 24214313, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.22670001, "heldPercentInsiders": 0.02123, "heldPercentInstitutions": 0.74120003, "shortRatio": 6.02, "shortPercentOfFloat": 0.2721, "impliedSharesOutstanding": 112310000, "bookValue": 7.542, "priceToBook": 3.8928668, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -128236000, "trailingEps": -1.16, "forwardEps": -1.51, "52WeekChange": -0.6246004, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 29.36, "targetHighPrice": 125.0, "targetLowPrice": 30.0, "targetMeanPrice": 90.26316, "targetMedianPrice": 100.0, "recommendationMean": 1.57895, "recommendationKey": "buy", "numberOfAnalystOpinions": 19, "totalCash": 851857984, "totalCashPerShare": 7.585, "totalDebt": 1000000, "quickRatio": 43.522, "currentRatio": 44.246, "debtToEquity": 0.118, "returnOnAssets": -0.117410004, "returnOnEquity": -0.14402, "freeCashflow": -98378376, "operatingCashflow": -133987000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VKTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Viking Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1430227800000, "postMarketChangePercent": 0.408716, "postMarketPrice": 29.48, "postMarketChange": 0.119999, "regularMarketChange": 0.74500084, "regularMarketDayRange": "29.1 - 30.28", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 4844451, "fiftyTwoWeekLowChange": 10.440001, "fiftyTwoWeekLowChangePercent": 0.5517971, "fiftyTwoWeekRange": "18.92 - 81.86", "fiftyTwoWeekHighChange": -52.5, "fiftyTwoWeekHighChangePercent": -0.6413389, "fiftyTwoWeekChangePercent": -62.46004, "earningsTimestamp": 1745438715, "earningsTimestampStart": 1753181940, "earningsTimestampEnd": 1753704000, "earningsCallTimestampStart": 1745440200, "earningsCallTimestampEnd": 1745440200, "isEarningsDateEstimate": true, "longName": "Viking Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1746230298, "regularMarketTime": 1746216001, "exchange": "NCM", "messageBoardId": "finmb_246791410", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.6035326, "regularMarketPrice": 29.36, "marketState": "CLOSED", "epsTrailingTwelveMonths": -1.16, "epsForward": -1.51, "epsCurrentYear": -1.84498, "priceEpsCurrentYear": -15.913452, "fiftyDayAverageChange": 2.6917, "fiftyDayAverageChangePercent": 0.10093257, "twoHundredDayAverageChange": -16.953201, "twoHundredDayAverageChangePercent": -0.3660555, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "displayName": "Viking Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]